Annovis Bio (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company disclosed that it has achieved 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and has closed enrollment to new participants after reaching sufficient screening levels to meet enrollment goals.
In addition to the Alzheimer’s program, Annovis reported progress in its Parkinson’s disease open-label extension study, which has reached 40% enrollment. The company also noted new biomarker initiatives and AI-powered digital monitoring as it continues advancing buntanetap toward potential regulatory submission.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Headquartered in Malvern, Pennsylvania, Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap, is designed to target multiple toxic proteins that contribute to neurodegeneration.
The progress in enrollment brings Annovis closer to potential regulatory submission, which could have significant implications for patients suffering from Alzheimer’s and Parkinson’s diseases. Currently, treatments for these conditions are limited, and a therapy that addresses underlying disease mechanisms could represent a major advancement.
For more information about Annovis Bio and its programs, visit the company’s website at www.annovisbio.com. The full press release is available at https://ibn.fm/M77X4.
